Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.46 |
| ▸ | NPY1R | P25929 | 10/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.46 |
| ▸ | NPY2R | P49146 | 6/20 | 0.46 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leupeptin SCHEMBL13933715 | 1.00 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| Leupeptin SCHEMBL11021602 | 1.00 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| Leupeptin SCHEMBL4669504 | 1.00 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| Leupeptin SCHEMBL11596919 | 0.99 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL3308386 | 0.99 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30643187 | 0.99 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL16316642 | 0.94 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| Leupeptin SCHEMBL25361 | 0.94 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL11094153 | 0.92 | SMN1; SMN2 (0.42) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL24178182 | 0.92 | BACE1 (0.44) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2416765-B1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS INC (US) | 2016-03-30 | — | — | EP | claimed |
| US-9198907-B2 | Combinations of a HCV inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent | PTC THERAPEUTICS, INC. (US) | 2015-12-01 | — | — | US | claimed |
| US-8841302-B2 | HCV inhibitor and therapeutic agent combinations | PTC THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | claimed |
| US-20120087893-A1 | COMBINATIONS OF A HCV INHIBITOR SUCH AS BICYCLIC PYRROLE DERIVATIVES AND A THERAPEUTIC AGENT | PTC THERAPEUTICS, INC. (US) | 2012-04-12 | — | — | US | claimed |
| US-20120070412-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-03-22 | — | — | US | claimed |
| EP-2416765-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | claimed |
| EP-2416772-A1 | COMBINATIONS OF A HCV INHIBITOR SUCH AS BICYCLIC PYRROLE DERIVATIVES AND A THERAPEUTIC AGENT | PTC Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | claimed |
| US-20110183915-A1 | Small Molecule Cancer Treatments that cause Necrosis in Cancer Cells but do not Affect Normal Cells | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2011-07-28 | — | — | US | claimed |
| WO-2010117936-A1 | COMBINATIONS OF A HCV INHIBITOR SUCH AS BICYCLIC PYRROLE DERIVATIVES AND A THERAPEUTIC AGENT | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| WO-2010117939-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| EP-2224961-A1 | SMALL MOLECULE CANCER TREATMENTS THAT CAUSE NECROSIS IN CANCER CELLS BUT DO NOT AFFECT NORMAL CELLS | The Research Foundation of the State University of New York (US) | 2010-09-08 | — | — | EP | claimed |
| WO-2009070650-A1 | SMALL MOLECULE CANCER TREATMENTS THAT CAUSE NECROSIS IN CANCER CELLS BUT DO NOT AFFECT NORMAL CELLS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2009-06-04 | — | — | WO | claimed |
| US-20080311036-A1 | Imaging of Neural and Organ Injury or Damage | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-12-18 | — | — | US | claimed |
| EP-1378242-B1 | Methods and compositions for the stabilization of brain natriuretic peptide (BNP) in blood samples | BAYER CORP (US) | 2006-12-27 | — | — | EP | claimed |
| WO-2006122237-A2 | IMAGING OF NEURAL AND ORGAN INJURY OR DAMAGE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2006-11-16 | — | — | WO | claimed |
| US-20040067889-A1 | Stabilization of brain natriuretic peptide (BNP) in blood samples, methods and compositions related thereto | BAYER CORPORATION | 2004-04-08 | — | — | US | claimed |
| EP-1378242-A1 | Methods and compositions for the stabilization of brain natriuretic peptide (BNP) in blood samples | BAYER CORPORATION (US) | 2004-01-07 | — | — | EP | claimed |
| US-4066507-A | AEROBIC CULTURING STREPTOMYCES | NIPPON KAYAKU KABUSHIKI KAISHA (JA) | 1978-01-03 | — | — | US | claimed |
| JP-58038219-A | — | — | None | — | — | JP | disclosed |
| US-4066507-A | AEROBIC CULTURING STREPTOMYCES | NIPPON KAYAKU KABUSHIKI KAISHA (JA) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183915-A1 | Small Molecule Cancer Treatments that cause Necrosis in Cancer Cells but do not Affect Normal Cells | HMGB2, HMGB1, HMGB3 | NPY4R 4820/4885NPY1R 4835/4885NPY5R 4779/4885 |
| US-20120070412-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | NPY4R 4626/4885NPY1R 4671/4885NPY5R 4625/4885 |
| US-20120087893-A1 | COMBINATIONS OF A HCV INHIBITOR SUCH AS BICYCLIC PYRROLE DERIVATIVES AND A THERAPEUTIC AGENT | PREP, ENPEP, DNPEP | NPY4R 4140/4885NPY1R 4377/4885NPY5R 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.